Upcoming EventsMore >>
There are currently no events scheduled.
Recent NewsMore >>
DateTitle 
10/01/14The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia Phase 3 TESLA Data Show Evolocumab Significantly Reduced LDL-C by 31 Percent Compared to Placebo in Patients With Homozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 a... 
Printer Friendly Version
10/01/14Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel® (etanercept) and ABP 501 (adalimumab biosimilar) at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to deliver... 
Printer Friendly Version
09/24/14Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they will discuss a su... 
Printer Friendly Version
09/22/14Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab
FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the tr... 
Printer Friendly Version
What's New
09/30/14
Download Documentation 2003 – 2013 EPS Reconciliation
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
Investor Insights Newsletters
DateTitle
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
04/30/14
Download Documentation Investor Insights Newsletter - Q1 2014
02/11/14
Download Documentation Investor Insights Newsletter - Q4 2013
10/31/13
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.